$BMY Recent News Market rookie Five Prime's shares surge

New Post Public Reply Private Reply Replies (0) Message Board

Mar 20, 2014 at 9:41 PM

$BMY Recent News

Market rookie Five Prime's shares surge on deal with Bristol-Myers 12:01 p.m. March 17, 2014 - Russ Britt
RadioShack sinks; J.C. Penney gains on S&P outlook hike 5:19 p.m. March 4, 2014 - Sue Chang
Bristol-Myers plans late-stage tests on Yervoy as lung-cancer treatment 5:01 p.m. March 4, 2014 - Russ Britt
Billionaire Stan Druckenmiller's recent moves 12:50 p.m. Feb. 24, 2014 - Insider Monkey
Feds, pharma rivals team up on Alzheimer's 3:32 p.m. Feb. 6, 2014 - Elizabeth O'Brien
Merck hits a new high as analyst sees opening for new cancer drug 12:16 p.m. Jan. 27, 2014 - Russ Britt
U.S. stocks tumble; Dow drops 318 points 6:29 p.m. Jan. 24, 2014 - Anora Mahmudova
Juniper buoyed by Jana stake; Herbalife loss grows 4:50 p.m. Jan. 24, 2014 - Sue Chang
U.S. stock futures trim losses ahead of market open 9:57 a.m. Jan. 24, 2014 - Barbara Kollmeyer
Beam, Honeywell, Procter & Gamble are stocks to watch 6:38 a.m. Jan. 24, 2014 - Sue Chang
AstraZeneca, Bristol-Myers Secure EU OK for Xigduo 3:44 a.m. Jan. 22, 2014 - MarketWatch.com
‘Sloppy’ market turns to consumer, tech earnings 9:01 a.m. Jan. 19, 2014 - Wallace Witkowski
America's best and most generous 401(k)s 3:30 p.m. Jan. 15, 2014 - Anne Tergesen
Merck initiates melanoma filing with FDA 12:45 p.m. Jan. 13, 2014 - Tess Stynes
Statin usefulness questioned, but patent expirations may ease pain 2:02 p.m. Jan. 8, 2014 - Russ Britt
Not all pharmaceuticals are created equal 1:40 p.m. Dec. 26, 2013 - The Trading Deck
FTSE 100 rises, shaking off retail data after Fed taper 1:06 p.m. Dec. 19, 2013 - Sara Sjolin
European stocks rally on Fed taper, rate views 1:00 p.m. Dec. 19, 2013 - Sara Sjolin
AstraZeneca to buy Bristol-Myers diabetes-JV stake 4:25 a.m. Dec. 19, 2013 - MarketWatch.com
Pfizer and Kaiser: They not only rhyme, they're in sync with workers 12:12 p.m. Dec. 10, 2013 - Russ Britt

Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Laggard 5:01 p.m. Today - TheStreet.com
Gilead's HCV Challengers Near The Starting Gate 4:28 p.m. March 19, 2014 - Investors Business Daily
Veteran Investor's Top Biotech and Drug Stocks 7:57 a.m. March 19, 2014 - Barrons.com
Gilead's HCV Challengers Near The Starting Gate 7:02 a.m. March 19, 2014 - Investors Business Daily
Cramer's Mad Money - Profits, Not Putin (3/18/14) 6:18 a.m. March 19, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Profits Still Matter 8:07 p.m. March 18, 2014 - TheStreet.com
Bristol-Myers, Five Prime In Cancer Pact 9:35 a.m. March 17, 2014 - The Wall Street Journal Interactive Edition
Bristol-Myers and Five Prime ink collaboration 7:28 a.m. March 17, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan 8:24 p.m. March 14, 2014 - TheStreet.com
Bristol-Myers and Pfizer Win Approval of New Indication for Eliquis 5:28 p.m. March 14, 2014 - Wall St. Cheat Sheet
Big Pharma drug clears regulatory hurdle 1:52 p.m. March 14, 2014 - Seeking Alpha
Insider Trading Alert - UNM, SEM And BMY Traded By Insiders 12:30 p.m. March 14, 2014 - TheStreet.com
BMY May 2nd Options Begin Trading 11:56 a.m. March 13, 2014 - TheStreet.com
Pfizer Breast-Cancer Drug To Show If It's For Real 4:51 p.m. March 10, 2014 - Investors Business Daily
3 Stocks Reiterated As A Buy: BMY, CAT, AXP 3:28 p.m. March 10, 2014 - TheStreet.com
On the hunt with the "pharmaceutical scouts" 10:00 a.m. March 10, 2014 - Seeking Alpha
Four Upcoming Catalysts That Could Move Pharmaceutical Stocks 8:19 a.m. March 10, 2014 - 247WallSt.com
Pharmaceutical Scouts Chase Hot Prospects 10:38 p.m. March 9, 2014 - The Wall Street Journal Interactive Edition
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine 10:49 a.m. March 7, 2014 - TheStreet.com
Total Dividend Return Will Guide My 2014 Investment Decisions 9:59 p.m. March 6, 2014 - Seeking Alpha

Trace One Names Mark Martini as Vice President of North America to Lead Sales and Customer Development 9:01 a.m. Today - BusinessWire - BZX
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway 8:15 a.m. March 19, 2014 - GlobeNewswire
Health Care Stocks Review -- Research on Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Eli Lilly 8:00 a.m. March 19, 2014 - PR Newswire - PRF
Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways 6:59 a.m. March 17, 2014 - BusinessWire - BZX
Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways 6:59 a.m. March 17, 2014 - GlobeNewswire
U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery 1:00 p.m. March 14, 2014 - BusinessWire - BZX
Investment Grants, Data Presentations, Clinical Study Results, and Collaborative Programs - Analyst Notes on UnitedHealth Group, Bristol-Myers Squibb, AbbVie, Cigna, and OXiGENE 8:00 a.m. March 14, 2014 - PR Newswire - PRF
Pharma-Biotech Industry Helps Drive $14.4 Billion Industrial Project Activity in Massachusetts, an Industrial Info News Alert 6:30 a.m. March 10, 2014 - Marketwire
Medivir: SVR12 Results from a Phase IIa Study Evaluating Simeprevir and Daclatasvir in Hepatitis C Patients of Genotype 1 Have Been Presented 12:30 p.m. March 4, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Announces Dividend 4:30 p.m. March 3, 2014 - BusinessWire - BZX
LUNGevity Foundation Receives Major Grant for Education Initiative 1:53 p.m. March 3, 2014 - PR Newswire - PRF
Bristol-Myers Squibb Announces Charitable Donation of $1 Million to Support Immuno-Oncology Education for Patients and Caregivers 7:30 a.m. March 3, 2014 - BusinessWire - BZX
Mead Johnson Nutrition Expands Board and Appoints Michael Grobstein as Director 10:15 a.m. Feb. 28, 2014 - BusinessWire - BZX
Aethlon Medical Expands Clinical Network Through DaVita Agreement 3:01 p.m. Feb. 26, 2014 - ACCESSWIRE
U.S. FDA approves orphan drug MyaleptTM (metreleptin for injection) 2:05 p.m. Feb. 25, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis C 8:30 a.m. Feb. 24, 2014 - BusinessWire - BZX
In a Subanalysis, Eliquis® (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation 11:06 a.m. Feb. 21, 2014 - BusinessWire - BZX
Bristol-Myers Squibb to Present at Cowen and Company 34th Annual Global Health Care Conference 2:00 p.m. Feb. 20, 2014 - BusinessWire - BZX
Bristol-Myers Squibb to Present at Citi 2014 Global Health Care Conference 3:30 p.m. Feb. 14, 2014 - BusinessWire - BZX
Galectin Therapeutics Leaps Ahead with SBH Sciences Partnership 11:02 a.m. Feb. 13, 2014 - ACCESSWIRE

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ePlus Wins Big: First Ambassador Partner for Everpure

ePlus Breaks Ground with Everpure There's a new chapter unfolding in the tech sector, and ePlus has carved its name on the marquee. Achieving the exclusive Ambassador Partner Status with Everpure, ePlus becomes the first in North America to hit this high note. In the crowded room of tech partnerships, this isn't just a pat on the back—it's a gold star that screams...

Herzog Joins Greenberg Traurig: A Litigation Powerhouse

Greenberg Traurig Welcomes David M. Herzog to the Team Ah, the rat race of litigation just got a bit fiercer with Greenberg Traurig's latest acquisition: David M. Herzog. This isn’t just another lawyer joining the ranks; Herzog's a dynamo, coming in hot from the U.S. Attorney's Office, right onto the battlefield of corporate litigation. Why Herzog's Move Matters...

Tahoe Truckee Life TV Series Elevates Local Flavor

Meet “Tahoe Truckee Life” Kane Schaller, the face of the Tahoe Truckee Life series, is giving folks a front-row seat to the lives and landscapes that make the Reno-Tahoe region buzz. Now, I've seen shows trying to pull this off, but this one might just spark something genuine if done right. The Real Deal on Reno-Tahoe The show airs on the REAL Shows Network—a...

Little Sunshine's Opens New School in Peoria, AZ

Betting On Early Childhood Education Little Sunshine's Playhouse breaks ground on a fresh hub of learning in Peoria, Arizona, and this is no small playdate. It's the dawn of another preschool institution aiming to mold the early years of countless kiddos. The gears turning behind this development are impressive by themselves, but it's what it means for Peoria's families...

Kroger's Strategic Shift: Ibbotson's Bold New Charge

Kroger Welcomes a Seasoned Retail Veteran Change often arrives with the dawn of new leadership. As Kroger takes a page from the playbook of large-scale retail transformation, they've enlisted Mark Ibbotson. Effective September 14, Ibbotson will step in as Executive Vice President and Chief Store Operations Officer. It's a roll of the dice that could either accelerate...

Capricor Faces Lawsuit: Investors Should Take Note

Capricor Therapeutics: A Rough Road Ahead If you've got skin in the game with Capricor Therapeutics, these latest developments might have you feeling a bit queasy. Forget the greasy diner fare today; this situation calls for some serious contemplation and maybe a bit of antacid. Over at NASDAQ:CAPR, the air is hot with allegations, stock price nosedives, and looming legal...

Sports CIOs Tackle Venue Tech Ownership Challenges

Untangling the Mess Behind Game Day Ever wonder why getting to your seat at a sports event feels seamless? It's like magic with your ticket appearing as a barcode on your phone, the concession stand knowing your order from last week's game, and sponsor ads personalized just for you. This is no easy feat. Behind the scenes, though, it's akin to a game of Twister. The...

Potassium Fluoride Market Growth Sparks Interest

Here's a story you might not have expected—potassium fluoride is finding its spotlight! With the market projected to tick upwards from USD 0.43 billion in 2026 to USD 0.51 billion by 2032, there's more here than meets the eye. A steady CAGR of 2.9% might not scream excitement, but steady growth often does the trick in chemicals. Why the Buzz Around Potassium Fluoride?...

MemoryDriver Relaunches with Navigation Challenge

MemoryDriver's Relight: A Blazing New Course in Brain Health Look at this: Evon Medics is back with a bang, and they're handing us more than just another mind-numbing app update. On September 15, they're flipping the switch on MemoryDriver, their revamped brain-training gig, with a national 'Beat the Clock' Challenge. It’s up for grabs, totally free, and full of...

Médunik Canada Boosts Dravet Syndrome Support with Biocodex

Breaking Down the Exclusive Médunik-Biocodex Partnership Listen, when a company like Médunik Canada, firmly rooted in Blainville, QC, throws its weight behind a rare disease drug like Diacomit®, folks in the industry take notice. Their recent handshake with Biocodex isn't just small talk; it opens doors to change how Dravet syndrome is managed across Canada. This new...